Monitor SEC filings for the prospectus supplement to assess offering size, pricing, and dilution impact. Given RVPH's small market cap ($14M), even a modest offering could result in significant dilution if priced near current levels.
RVPH drugs
RVPH drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 19 $0.8300entry
- T+1 · 8mo ago −3.61%α −1.87% · $0.8000
- T+5 · 8mo ago −6.02%α −3.81% · $0.7800
- T+20 · 7mo ago +2.41%α −5.21% · $0.8500
- T+60 · 5mo ago −15.66%α −30.01% · $0.7000
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Reviva Pharmaceuticals (RVPH) announced plans for a public offering of common stock and warrants, with proceeds intended to fund its Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia and general corporate purposes. The offering size, pricing, and terms have not been disclosed, and completion is subject to market conditions.
Key Facts
- Reviva Pharmaceuticals is conducting a public offering of common stock (or equivalents) and warrants.
- All securities are being offered by the company; no selling shareholders mentioned.
- A.G.P./Alliance Global Partners is the sole placement agent.
- Proceeds will fund the RECOVER-2 Phase 3 trial for brilaroxazine, R&D, and general corporate purposes.
- Offering will be made under an effective shelf registration (Form S-3, filed Feb 2024), with a preliminary prospectus supplement to be filed.
- No specific offering size, price, or number of shares disclosed; terms subject to market conditions.
Financial Impact
Dilutive to existing shareholders once priced and completed; magnitude unknown pending final terms.
Risk Factors
- Potential for substantial dilution if offering is large relative to current market cap or priced at a discount.
- Equity offering in a weak market environment may depress stock price ahead of and after pricing.
- No assurance the offering will be completed due to market or regulatory conditions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258600 |
Track record
12 reports on RVPH
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 No price data
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3400 Now $0.3504 +3.07% settles Feb 11
- Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
- Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
- May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
- May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
- Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
- Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
- Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers